Tumour cell detection in G-CSF mobilised stem cell harvests of patients with breast cancer.
Peripheral blood stem cells were mobilised with G-CSF from steady-state haemopoiesis after previous anthracyclin-containing standard dose chemotherapy in patients with high-risk breast cancer. 48 samples were obtained from patients with stage II-III breast cancer and > or = 10 lymph nodes, 15 samples from patients with chemotherapy sensitive metastatic disease, and 13 samples from women with inflammatory breast cancer. 44 samples were first or single leukaphereses and 32 samples were second or third harvests. Aliquots were searched for contaminating tumour cells by immunocytochemistry (IC) and cytokeratin-19 reverse transcriptase polymerase chain reaction rtPCR). The median count of MNCs examined by IC was 2 x 10(6); cDNA prepared from 2 x 10(7) cells was subjected to PCR. Fifty-nine samples were examined by immunocytochemistry, 36 samples by rtPCR, and 19 samples by both techniques. Samples investigated by IC and rtPCR were judged as positive if there was at least one positive test. On the whole, 42/79 (55.3%) of the samples were positive with an insignificant trend to a higher positivity rate in second or subsequent leukaphereses (52.3% vs 59.3%). The median tumour cell load per 10(6) MNCs was low with 0.5 (0-7) cells in all, and a total of 2.2 (0.5-7) cells in positive specimen. Differences in the cancer cell load of first and subsequent leukaphereses and between subgroups of patients were not found. PCR and IC gave consistent results in 63.2%. This phenomenon can be explained by the greater sensitivity of the molecular method and by a Poisson distribution of coharvested tumour cells in samples. Tumour cell contamination in G-CSF mobilised stem cells from patients with breast cancer from steady state haemopoiesis after preceding anthacyclin-containing chemotherapy is frequent, but the tumour cell load is low. To allow a comparison of different studies dealing with cancer cell contamination in stem cells, standardisation of assays is necessary.
Krüger
W
W
Bone Marrow Transplantation Centre, Department of Haematology/Oncology, University Hospital Eppendorf, Hamburg, Germany. krueger@uke.uni-hamburg.de
Tögel
F
F
Kröger
N
N
Rössing
S
S
Gieseking
F
F
Gutensohn
K
K
Lindner
C
C
Jänicke
F
F
Zander
A R
AR
D001943:Breast Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000473:pathology; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor; D019650:Hematopoietic Stem Cell Mobilization; D006801:Humans; D007150:Immunohistochemistry; D007633:Keratins; D007937:Leukapheresis; D007963:Leukocytes, Mononuclear / Q000473:pathology*; D020133:Reverse Transcriptase Polymerase Chain Reaction
D016179:Granulocyte Colony-Stimulating Factor; D007633:Keratins